In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic
University Medical Center Schleswig-Holstein
Kiel, Germany
PUBLICATION
Why this article was chosen
Commentary
Sudden pandemic situations are a significant threat to people with known chronic illnesses representing an additional unexpected burden. Those with limited psycho-social resources and lower resilience are more likely to withdraw from regular care and seek help or information. However, the high proportion of people with psoriasis having interrupted access to care (40.1%), as described in the report by Cook et al, is unexpected. Still, in this report, the data were collected from a multi-national survey (PsoProtectMe) in 89 countries worldwide on 802 patients with psoriasis. In addition, psoriasis patients having interrupted access to care had increased vaccine hesitancy, were more prevalent in non-white ethnic groups, had shorter disease duration, and were less likely to take systemic immunosuppressants.
It is important to note that the disruption of care can be bi-directional. The affected people stopped seeing their treating physicians, but physicians also canceled patients’ appointments. It is worth noting that younger people with psoriasis and more severe disease were more likely to discontinue care, and the rate of vaccine hesitancy was higher in this group. The authors did not speculate about factors driving this coincident finding. This may be due to greater engagement of younger people through social media, in which worries and concerns (e.g., a new type of vaccine, fear of adverse events, etc) are intensively discussed and amplified without direct physician’s input. However, and encouragingly, the rate of vaccine hesitancy, which was 8.3% in the entire patient population, seems low and provides evidence that stakeholders providing care in the different healthcare systems can get through to people with psoriasis.
As reported by Cook et al, these data help identify groups that need correct and unbiased information based on solid and accurate evidence-based medicine.
Categories
Recent Posts
Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis
Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research
Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD
Also Read
Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares
Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.
Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics
Nicole Ward explores groundbreaking psoriatic disease research methods published in recent literature. Discover how Spatial Transcriptomics and Single Cell Sequencing unveil new cellular players and pathways, opening doors to novel drug targets and advancing psoriasis research and medicine.
Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Subscribe to the IPC Newsletter